Find disease awareness content and relevant supporting materials

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

For the first time ever in a human, doctors have performed coronary artery bypass grafting without having to cut through the patient's chest, similar to how many aortic valve replacement procedures are now done.

The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Enhertu. The marketing authorisation holder for this medicinal product is Daiichi Sankyo Europe GmbH and licensee is AstraZeneca

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

National Institute for Health and Care Excellence (NICE) recommends;Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Technology appraisal guidance [TA786]Published: 27 April 2022.

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast cancer who have received a prior therapy in the metastatic setting

Astellas Pharma Inc. announced dosing of the first patient in the HIGHLIGHT 1 Phase III pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy